AI assistant
Sending…
Actinium Pharmaceuticals, Inc. — Director's Dealing 2017
Jun 15, 2017
34570_dirs_2017-06-15_4d1060dd-0269-4807-919c-d211ef0a08b6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2017-06-15
Reporting Person: Berger Mark Stanley (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-06-15 | Common stock | P | 5000 | $1.11 | Acquired | 5000 | Direct |
More from Actinium Pharmaceuticals, Inc.
Regulatory Filings
2026
May 29
Annual Report
2026
Mar 30
Regulatory Filings
2026
Mar 26
Regulatory Filings
2026
Feb 13
Regulatory Filings
2025
Nov 26
Interim / Quarterly Report
2025
Nov 14
Annual Report
2025
Nov 5
Proxy Solicitation & Information Statement
2025
Nov 5
Director's Dealing
2025
Aug 20
Interim / Quarterly Report
2025
Aug 8